Advanced congestive heart failure (CHF) and chronic kidney disease (CKD) are characterized by increased angiotensin II (Ang II) levels and are often accompanied by significant skeletal muscle wasting that negatively impacts mortality and morbidity. Both CHF and CKD patients have respiratory muscle dysfunction, however the potential effects of Ang II on respiratory muscles are unknown. We investigated the effects of Ang II on diaphragm muscle in FVB mice. Ang II induced significant diaphragm muscle wasting (18.7±1.6% decrease in weight at one week) and reduction in fiber cross-sectional area. Expression of the E3 ubiquitin ligases atrogin-1 and muscle ring finger-1 (MuRF-1) and of the pro-apoptotic factor BAX was increased after 24 h of Ang II infusion (4.4±0.3 fold, 3.1±0.5 fold and 1.6±0.2 fold, respectively, compared to sham infused control) suggesting increased muscle protein degradation and apoptosis. In Ang II infused animals, there was significant regeneration of injured diaphragm muscles at 7 days as indicated by an increase in the number of myofibers with centralized nuclei and high expression of embryonic myosin heavy chain (E-MyHC, 11.2±3.3 fold increase) and of the satellite cell marker M-cadherin (59.2±22.2% increase). Furthermore, there was an increase in expression of insulin-like growth factor-1 (IGF-1, 1.8±0.3 fold increase) in Ang II infused diaphragm, suggesting the involvement of IGF-1 in diaphragm muscle regeneration. Bone-marrow transplantation experiments indicated that although there was recruitment of bone-marrow derived cells to the injured diaphragm in Ang II infused mice (267.0±74.6% increase), those cells did not express markers of muscle stem cells or regenerating myofibers. In conclusion, Ang II causes marked diaphragm muscle wasting, which may be important for the pathophysiology of respiratory muscle dysfunction and cachexia in conditions such as CHF and CKD.
References
[1]
Mancini DM, Henson D, LaManca J, Levine S (1992) Respiratory muscle function and dyspnea in patients with chronic congestive heart failure. Circulation 86: 909–918.
[2]
Meyer FJ, Borst MM, Zugck C, Kirschke A, Schellberg D, et al. (2001) Respiratory muscle dysfunction in congestive heart failure: clinical correlation and prognostic significance. Circulation 103: 2153–2158.
[3]
Strassburg S, Springer J, Anker SD (2005) Muscle wasting in cardiac cachexia. Int J Biochem Cell Biol 37: 1938–1947.
[4]
van Hees HW, van der Heijden HF, Ottenheijm CA, Heunks LM, Pigmans CJ, et al. (2007) Diaphragm single-fiber weakness and loss of myosin in congestive heart failure rats. Am J Physiol Heart Circ Physiol 293: H819–828.
[5]
Zhang L, Wang XH, Wang H, Du J, Mitch WE (2010) Satellite cell dysfunction and impaired IGF-1 signaling cause CKD-induced muscle atrophy. J Am Soc Nephrol 21: 419–427.
[6]
Ottenheijm CA, Heunks LM, Dekhuijzen PN (2007) Diaphragm muscle fiber dysfunction in chronic obstructive pulmonary disease: toward a pathophysiological concept. Am J Respir Crit Care Med 175: 1233–1240.
[7]
Tisdale MJ (2009) Mechanisms of cancer cachexia. Physiol Rev 89: 381–410.
[8]
Pocock SJ, McMurray JJ, Dobson J, Yusuf S, Granger CB, et al. (2008) Weight loss and mortality risk in patients with chronic heart failure in the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme. Eur Heart J 29: 2641–2650.
[9]
McKenzie DK, Butler JE, Gandevia SC (2009) Respiratory muscle function and activation in chronic obstructive pulmonary disease. J Appl Physiol 107: 621–629.
[10]
Hughes PD, Polkey MI, Harrus ML, Coats AJ, Moxham J, et al. (1999) Diaphragm strength in chronic heart failure. Am J Respir Crit Care Med 160: 529–534.
[11]
Glass D, Roubenoff R (2010) Recent advances in the biology and therapy of muscle wasting. Ann N Y Acad Sci 1211: 25–36.
[12]
Sandri M (2008) Signaling in muscle atrophy and hypertrophy. Physiology (Bethesda) 23: 160–170.
[13]
Glass DJ (2003) Signalling pathways that mediate skeletal muscle hypertrophy and atrophy. Nat Cell Biol 5: 87–90.
[14]
Masson S, Latini R, Bevilacqua M, Vago T, Sessa F, et al. (1998) Within-patient variability of hormone and cytokine concentrations in heart failure. Pharmacol Res 37: 213–217.
[15]
Roig E, Perez-Villa F, Morales M, Jimenez W, Orus J, et al. (2000) Clinical implications of increased plasma angiotensin II despite ACE inhibitor therapy in patients with congestive heart failure. Eur Heart J 21: 53–57.
[16]
Song YH, Li Y, Du J, Mitch WE, Rosenthal N, et al. (2005) Muscle-specific expression of IGF-1 blocks angiotensin II-induced skeletal muscle wasting. J Clin Invest 115: 451–458.
[17]
Yoshida T, Semprun-Prieto L, Sukhanov S, Delafontaine P (2010) IGF-1 prevents ANG II-induced skeletal muscle atrophy via Akt- and Foxo-dependent inhibition of the ubiquitin ligase atrogin-1 expression. Am J Physiol Heart Circ Physiol 298: H1565–1570.
[18]
Barton ER, Morris L, Musaro A, Rosenthal N, Sweeney HL (2002) Muscle-specific expression of insulin-like growth factor I counters muscle decline in mdx mice. J Cell Biol 157: 137–148.
[19]
Musaro A, McCullagh K, Paul A, Houghton L, Dobrowolny G, et al. (2001) Localized Igf-1 transgene expression sustains hypertrophy and regeneration in senescent skeletal muscle. Nat Genet 27: 195–200.
[20]
Chakravarthy MV, Abraha TW, Schwartz RJ, Fiorotto ML, Booth FW (2000) Insulin-like growth factor-I extends in vitro replicative life span of skeletal muscle satellite cells by enhancing G1/S cell cycle progression via the activation of phosphatidylinositol 3′-kinase/Akt signaling pathway. J Biol Chem 275: 35942–35952.
[21]
Chakravarthy MV, Davis BS, Booth FW (2000) IGF-I restores satellite cell proliferative potential in immobilized old skeletal muscle. J Appl Physiol 89: 1365–1379.
[22]
Tidball JG (2005) Inflammatory processes in muscle injury and repair. Am J Physiol Regul Integr Comp Physiol 288: R345–353.
[23]
Ferrari G, Cusella-De Angelis G, Coletta M, Paolucci E, Stornaiuolo A, et al. (1998) Muscle regeneration by bone marrow-derived myogenic progenitors. Science 279: 1528–1530.
[24]
Charge SB, Rudnicki MA (2004) Cellular and molecular regulation of muscle regeneration. Physiol Rev 84: 209–238.
[25]
Hawke TJ, Garry DJ (2001) Myogenic satellite cells: physiology to molecular biology. J Appl Physiol 91: 534–551.
[26]
Otto A, Collins-Hooper H, Patel K (2009) The origin, molecular regulation and therapeutic potential of myogenic stem cell populations. J Anat 215: 477–497.
[27]
Sherwood RI, Christensen JL, Conboy IM, Conboy MJ, Rando TA, et al. (2004) Isolation of adult mouse myogenic progenitors: functional heterogeneity of cells within and engrafting skeletal muscle. Cell 119: 543–554.
[28]
Sacco A, Doyonnas R, Kraft P, Vitorovic S, Blau HM (2008) Self-renewal and expansion of single transplanted muscle stem cells. Nature 456: 502–506.
[29]
Brink M, Wellen J, Delafontaine P (1996) Angiotensin II causes weight loss and decreases circulating insulin-like growth factor I in rats through a pressor-independent mechanism. J Clin Invest 97: 2509–2516.
[30]
Brink M, Price SR, Chrast J, Bailey JL, Anwar A, et al. (2001) Angiotensin II induces skeletal muscle wasting through enhanced protein degradation and down-regulates autocrine insulin-like growth factor I. Endocrinology 142: 1489–1496.
[31]
Semprun-Prieto LC, Sukhanov S, Yoshida T, Rezk BM, Gonzalez-Villalobos RA, et al. (2011) Angiotensin II induced catabolic effect and muscle atrophy are redox dependent. Biochem Biophys Res Commun 409: 217–221.
[32]
Attaix D, Ventadour S, Codran A, Bechet D, Taillandier D, et al. (2005) The ubiquitin-proteasome system and skeletal muscle wasting. Essays Biochem 41: 173–186.
[33]
Watchko JF, O'Day TL, Hoffman EP (2002) Functional characteristics of dystrophic skeletal muscle: insights from animal models. J Appl Physiol 93: 407–417.
[34]
Acharyya S, Villalta SA, Bakkar N, Bupha-Intr T, Janssen PM, et al. (2007) Interplay of IKK/NF-kappaB signaling in macrophages and myofibers promotes muscle degeneration in Duchenne muscular dystrophy. J Clin Invest 117: 889–901.
[35]
Scime A, Caron AZ, Grenier G (2009) Advances in myogenic cell transplantation and skeletal muscle tissue engineering. Front Biosci 14: 3012–3023.
[36]
Cornelison DD, Wold BJ (1997) Single-cell analysis of regulatory gene expression in quiescent and activated mouse skeletal muscle satellite cells. Dev Biol 191: 270–283.
[37]
Beauchamp JR, Heslop L, Yu DS, Tajbakhsh S, Kelly RG, et al. (2000) Expression of CD34 and Myf5 defines the majority of quiescent adult skeletal muscle satellite cells. J Cell Biol 151: 1221–1234.
[38]
Hayashi S, Aso H, Watanabe K, Nara H, Rose MT, et al. (2004) Sequence of IGF-I, IGF-II, and HGF expression in regenerating skeletal muscle. Histochem Cell Biol 122: 427–434.
[39]
Honda H, Abe S, Ishida R, Watanabe Y, Iwanuma O, et al. (2010) Expression of HGF and IGF-1 during regeneration of masseter muscle in mdx mice. J Muscle Res Cell Motil 31: 71–77.
[40]
Du J, Meng XP, Delafontaine P (1996) Transcriptional regulation of the insulin-like growth factor-I receptor gene: evidence for protein kinase C-dependent and -independent pathways. Endocrinology 137: 1378–1384.
[41]
Scheidegger KJ, Du J, Delafontaine P (1999) Distinct and common pathways in the regulation of insulin-like growth factor-1 receptor gene expression by angiotensin II and basic fibroblast growth factor. J Biol Chem 274: 3522–3530.
[42]
Schillaci R, Brocardo MG, Galeano A, Roldan A (1998) Downregulation of insulin-like growth factor-1 receptor (IGF-1R) expression in human T lymphocyte activation. Cell Immunol 183: 157–161.
[43]
LaBarge MA, Blau HM (2002) Biological progression from adult bone marrow to mononucleate muscle stem cell to multinucleate muscle fiber in response to injury. Cell 111: 589–601.
[44]
Camargo FD, Green R, Capetanaki Y, Jackson KA, Goodell MA (2003) Single hematopoietic stem cells generate skeletal muscle through myeloid intermediates. Nat Med 9: 1520–1527.
[45]
Musaro A, Giacinti C, Borsellino G, Dobrowolny G, Pelosi L, et al. (2004) Stem cell-mediated muscle regeneration is enhanced by local isoform of insulin-like growth factor 1. Proc Natl Acad Sci U S A 101: 1206–1210.
[46]
Wagers AJ, Conboy IM (2005) Cellular and molecular signatures of muscle regeneration: current concepts and controversies in adult myogenesis. Cell 122: 659–667.
[47]
Gonzalez-Villalobos RA, Seth DM, Satou R, Horton H, Ohashi N, et al. (2008) Intrarenal angiotensin II and angiotensinogen augmentation in chronic angiotensin II-infused mice. Am J Physiol Renal Physiol 295: F772–779.
[48]
Graziani G, Badalamenti S, Del Bo A, Marabini M, Gazzano G, et al. (1993) Abnormal hemodynamics and elevated angiotensin II plasma levels in polydipsic patients on regular hemodialysis treatment. Kidney Int 44: 107–114.
[49]
Simoes e Silva AC, Diniz JS, Pereira RM, Pinheiro SV, Santos RA (2006) Circulating renin Angiotensin system in childhood chronic renal failure: marked increase of Angiotensin-(1–7) in end-stage renal disease. Pediatr Res 60: 734–739.
[50]
Wong E, Selig S, Hare DL (2011) Respiratory muscle dysfunction and training in chronic heart failure. Heart Lung Circ 20: 289–294.
[51]
Ottenheijm CA, Heunks LM, Li YP, Jin B, Minnaard R, et al. (2006) Activation of the ubiquitin-proteasome pathway in the diaphragm in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 174: 997–1002.
[52]
Vlahakos DV, Kosmas EN, Dimopoulou I, Ikonomou E, Jullien G, et al. (1999) Association between activation of the renin-angiotensin system and secondary erythrocytosis in patients with chronic obstructive pulmonary disease. Am J Med 106: 158–164.
[53]
Kanazawa H, Okamoto T, Hirata K, Yoshikawa J (2000) Deletion polymorphisms in the angiotensin converting enzyme gene are associated with pulmonary hypertension evoked by exercise challenge in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 162: 1235–1238.
[54]
McClung JM, Kavazis AN, DeRuisseau KC, Falk DJ, Deering MA, et al. (2007) Caspase-3 regulation of diaphragm myonuclear domain during mechanical ventilation-induced atrophy. Am J Respir Crit Care Med 175: 150–159.
